Failure of Recombinant Human Growth Hormone Treatment to Improve Congestive Heart Failure in Hypopituitarism

Abstract

Growth hormone (GH) deficiency decreases left ventricular (LV) contractility, induces LV chamber dilatation and promotes progression to congestive heart failure. It is, however, controversial, whether GH replacement therapy in addition to standard medical heart failure therapy should be considered as routine treatment in GH deficient patients with heart failure. In the present report of a 64-year-old GH deficient patient with heart failure, we demonstrate by using Doppler echocardiography, magnetic resonance imaging and ³¹P NMR spectroscopy that even a 12 month period of GH replacement therapy had no sustained effect on morphometric or functional parameters of LV performance nor on clinical signs or symptoms of heart failure. It is concluded that GH replacement therapy should currently not be regarded as standard heart failure therapy in patients with GH deficiency and should only be employed under careful monitoring including close follow-up in a standardized way.

Growth hormone - heart failure - replacement therapy - energy metabolism - hypopituitarism

References

• 1 Amato G, Carella C, Fazio S, La Montagna G, Cittadini A, Sabatini D, Marciano-Mone C, Sacca L, Bellastella A. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses.  J Clin Endocrinol Metab. 1993;  77 1671-1676
• 2 Attanasio A F, Lamberts S W, Matranga A M, Birkett M A, Bates P C, Valk N K, Hilsted J, Bengtsson B A, Strasburger C J. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group.  J Clin Endocrinol Metab. 1997;  82 82-88
• 3 Cittadini A, Cuocolo A, Merola B, Fazio S, Sabatini D, Nicolai E, Colao A, Longobard S, Lombardi G, Sacca L. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement.  Am J Physiol. 1994;  267 E219-225
• 4 Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart.  Clin Endocrinol (Oxf). 2001;  54 137-154
• 5 Cuneo R C, Wilmshurst P, Lowy C, McGauley G, Sonksen P H. Cardiac failure responding to growth hormone.  Lancet. 1989;  1 838-839
• 6 Duerr R L, Huang S, Miraliakbar H R, Clark R, Chien K R, Ross J. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure.  J Clin Invest. 1995;  95 619-627
• 7 Fazio S, Biondi B, Sabatini D, Cuocolo A, Tommaselli A P, Lombardi G, Sacca L. Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy.  J Clin Endocrinol Metab. 1996 a;  81 887-890
• 8 Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Sacca L. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy.  New Engl J Med. 1996 b;  334 809-814
• 9 Frustaci A, Perrone G A, Gentiloni N, Russo M A. Reversible dilated cardiomyopathy due to growth hormone deficiency.  Am J Clin Pathol. 1992;  97 503-511
• 10 Genth-Zotz S, Zotz R, Geil S, Voigtlander T, Meyer J, Darius H. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity.  Circulation. 1999;  99 18-21
• 11 Mathews L S, Enberg B, Norstedt G. Regulation of rat growth hormone receptor gene expression.  J Biol Chem. 1989;  264 9905-9910
• 12 Osterziel K J, Strohm O, Schuler J, Friedrich M, Hanlein D, Willenbrock R, Anker S D, Poole-Wilson P A, Ranke M B, Dietz R. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.  Lancet. 1998;  351 1233-1237
• 13 Rosen T, Bengtsson B A. Premature mortality due to cardiovascular disease in hypopituitarism.  Lancet. 1990;  336 285-288
• 14 Rudman D, Feller A G, Nagraj H S, Gergans G A, Lalitha P Y, Goldberg A F, Schlenker R A, Cohn L, Rudman I W, Mattson D E. Effects of human growth hormone in men over 60 years old.  New Engl J Med. 1990;  323 1-6
• 15 Sandstede J, Lipke C, Beer M, Hofmann S, Pabst T, Kenn W, Neubauer S, Hahn D. Age- and gender-specific differences in left and right ventricular cardiac function and mass determined by cine magnetic resonance imaging.  Eur Radiol. 2000;  10 438-442
• 16 Shen Y T, Wiedmann R T, Lynch J J, Grossman W, Johnson R G. GH replacement fails to improve ventricular function in hypophysectomized rats with myocardial infarction.  Am J Physiol. 1996;  271 H1721-1727
• 17 ter Maaten J C, de Boer H, Kamp O, Stuurman L, van der Veen E A. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency.  J Clin Endocrinol Metab. 1999;  84 2373-2380
• 18 Valcavi R, Gaddi O, Zini M, Iavicoli M, Mellino U, Portioli I. Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment.  J Clin Endocrinol Metab. 1995;  80 659-666